At GoBroad Medical Institute of Hematology (Shanghai Center), we are at the forefront of battling aggressive blood cancers, offering renewed hope through CAR T treatment for lymphoma. As a certified bone marrow transplantation center and a leader in hematologic oncology, we specialize in therapies that target relapsed or refractory lymphomas with precision and innovation. Led by Professor Wang Chun, whose 30-year legacy includes breakthroughs in hematopoietic stem cell transplantation and cellular immunotherapy, our team combines advanced science with compassionate care. With 32 laminar airflow transplant rooms, advanced diagnostics, and a 300-bed facility integrated into Shanghai’s medical insurance network, we deliver CAR T treatment for lymphoma that prioritizes safety, efficacy, and accessibility.

The Science of CAR T Treatment for Lymphoma: Precision from Start to Finish

CAR T treatment for lymphoma begins with understanding the unique biology of each patient’s cancer. At GoBroad, our diagnostic arsenal includes flow cytometry, genetic testing, and fluorescence in situ hybridization (FISH) to identify specific markers like CD19 or CD20 on lymphoma cells. These markers guide the engineering of CAR T cells—a process where a patient’s own T cells are reprogrammed to recognize and destroy cancerous cells. For example, in cases of refractory T-cell lymphoma, we tailor CAR T constructs to target uncommon antigens, maximizing tumor specificity. Post-infusion, our specialized labs monitor minimal residual disease (MRD) using PCR testing, allowing real-time adjustments to therapy. This precision ensures CAR T treatment for lymphoma is not just a last resort but a strategically timed intervention, often integrated with salvage chemotherapy or radiation to enhance outcomes.

Salvaging Hope in Complex and Relapsed Cases
Lymphoma that resists standard therapies demands ingenuity. Our expertise in CAR T treatment for lymphoma shines in treating relapsed or refractory cases, where conventional options have failed. Professor Wang’s team has pioneered protocols for elderly patients and those with comorbidities, who are often excluded from aggressive therapies. For instance, we modify lymphodepletion regimens—a critical step before CAR T infusion—to reduce toxicity in frail patients without compromising efficacy. In aggressive B-cell lymphomas, we combine CAR T treatment for lymphoma with bridging therapies like PD-1 inhibitors to prime the immune system, improving response rates. For high-risk T-cell lymphomas, our clinical trials explore dual-target CAR T therapies designed to overcome tumor escape mechanisms. This approach has changed outcomes for patients once deemed untreatable, offering durable remissions where hope was scarce.

Global Access and Seamless Care for International Patients

Geographical barriers should never block access to life-saving CAR T treatment for lymphoma. GoBroad’s Shanghai Center simplifies the journey for international patients through our dedicated service team, handling everything from visa support to insurance coordination. We accept real-time settlements for China’s national cross-regional medical insurance and direct billing for global commercial policies, minimizing financial stress. A patient from overseas with relapsed diffuse large B-cell lymphoma, for example, can undergo apheresis, CAR T cell manufacturing, and infusion—all within our facility—supported by multilingual staff and culturally sensitive care. Post-treatment, our remote monitoring system tracks recovery, ensuring continuity even after patients return home. Collaborations with institutions like the Shanghai Ruijin Hospital Blood Disease Medical Association further bolster our ability to adopt global innovations, making CAR T treatment for lymphoma at GoBroad both world-class and uniquely accessible.

Conclusion

Choosing GoBroad Medical Institute of Hematology (Shanghai Center) means partnering with a team that views CAR T treatment for lymphoma as more than a procedure—it’s a lifeline crafted with expertise and empathy. From molecular diagnostics to tailored infusion protocols and international patient support, we redefine what’s possible in lymphoma care. Whether confronting a first relapse or a decades-long battle, our fusion of innovation, multidisciplinary collaboration, and patient-first values offers a path to remission. Discover how GoBroad turns advanced science into tangible hope, one CAR T cell at a time. Here, we don’t just treat cancer; we rewrite futures.